Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Precigen $34 million follow-on offering
We advised Precigen on the SEC-registered offering
Generation Bio $237 million at-the-market offering
The shares are listed on Nasdaq
Bansk Group $1.5 billion going-private acquisition of PetIQ
We are advising Bansk Group on the transaction
Revolution Medicines $500 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
AC Immune $80 million at-the-market offering
We advised AC Immune on the offering
GSK collaboration with Flagship Pioneering
We are advising GSK on the transaction
Clariane €92 million reserved capital increase and €237 million rights offering
We advised Clariane on its refinancing transactions
IDEAYA Biosciences $302.5 million equity offering
The common stock is listed on the Nasdaq Global Select Market
Recursion Pharmaceuticals $230 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
InflaRx $75 million at-the-market offering
The shares are listed on the Nasdaq Global Market